New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Apollo Investment Corp (NASDAQ:AINV), IMRIS Inc (NASDAQ:IMRS), Orexigen Therapeutics, Inc (NASDAQ:OREX), Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)
Apollo Investment Corp (NASDAQ:AINV) showed a volume of 1.87 million shares by the end of last trade whereas the average volume of the stock remained 1.51 million shares. The stock opened the session at $8.97 but then moved to $9.01. At that price, the stock showed a positive performance of 0.11%. Apollo Investment Corporation (Apollo Investment) is a closed-end, non-diversified management investment company that has elected to be treated as a business development company. Its investment objective is to generate current income and capital appreciation.
Will AINV Continue To Move Higher? Find Out Here
IMRIS Inc (NASDAQ:IMRS) opened the session at $1.92 and closed the session at $2.07. The stock showed a positive performance of 7.81% in previous trading session. Traded with volume of 1.84 million shares in the prior session and the average volume of the stock remained 245,476.00 shares. IMRIS Inc. (IMRIS) designs, manufactures and markets the VISIUS Surgical Theatre, a multifunctional surgical environment that provides intraoperative vision to clinicians.
For How Long IMRS will fight for Profitability? Read This Trend Analysis report
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $6.86 and closed the session at $6.71. The stock showed a negative performance of -2.33% in previous trading session. Traded with volume of 1.82 million shares in the prior session and the average volume of the stock remained 2.49 million shares. The beta of the stock remained 2.11. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety,
Why Should Investors Buy OREX After the Recent Fall? Just Go Here and Find Out
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) the stock advanced 4.59% and finished the session at $8.66. Traded with volume of 1.87 million shares in the prior session and the average volume of the stock remained 769,958.00 shares. The beta of the stock remained 1.23. Prana Biotechnology Limited (Prana) is development stage company. The Company is engaged in develop therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer’s disease.
Will PRAN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)